ReviewHuman vaccines & immunotherapeutics2013
A critical literature review of health economic evaluations of rotavirus vaccination.
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic literature review and meta-analysis on the prevalence of rotavirus genotypes in Europe and the Middle East in the post-licensure period.Human vaccines & immunotherapeutics · 2024Pooled it
- Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.PharmacoEconomics · 2018Pooled it
- Review
- Epidemiology of group A rotavirus in children under five years of age with gastroenteritis in N'Djamena, Chad.BMC infectious diseases · 2024Article
- Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines.Journal of the Canadian Association of Gastroenterology · 2021Review
- Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.The Lancet. Global health · 2021Article
- Article
- Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs.PharmacoEconomics · 2021Article
- Primary care-based surveillance to estimate the proportion of rotavirus gastroenteritis among Latvian children below 5 years of age with acute gastroenteritis.Human vaccines & immunotherapeutics · 2019Observational
- Rotavirus infection.Nature reviews. Disease primers · 2017Review
- Re-evaluation of the cost-effectiveness and effects of childhood rotavirus vaccination in Norway.PloS one · 2017Article
- Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option.BMC infectious diseases · 2016Article
- Article
- Nosocomial rotavirus infection: An up to date evaluation of European studies.Human vaccines & immunotherapeutics · 2016Review
- Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?Applied health economics and health policy · 2016Article
- Alberta Provincial Pediatric EnTeric Infection TEam (APPETITE): epidemiology, emerging organisms, and economics.BMC pediatrics · 2015Article
- The Economic Value of Vaccination: Why Prevention is Wealth.Journal of market access & health policy · 2015Article
- Dissecting the indirect effects caused by vaccines into the basic elements.Human vaccines & immunotherapeutics · 2015Review
- Vaccination: the cornerstone of an efficient healthcare system.Journal of market access & health policy · 2015Article
- Do current cost-effectiveness analyses reflect the full value of childhood vaccination in Europe? A rotavirus case study.Human vaccines & immunotherapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two licensed vaccines are available to prevent RVGE in infants. A worldwide critical review of economic evaluations of these vaccines was conducted. The objective was to describe differences in methodologies, assumptions and inputs and determine the key factors driving differences in conclusions. 68 economic evaluations were reviewed. RV vaccination was found to be cost-effective in developing countries, while conclusions varied between studies in developed countries. Many studies found that vaccination was likely to be cost-effective under some scenarios, such as lower prices scenarios, inclusion of herd protection, and/or adoption of a societal perspective. Other reasons for variability included uncertainty around healthcare visits incidence and lack of consensus on quality of life (QoL) valuation for infants and caregivers. New evidence on the vaccination effectiveness in real-world, new ways of modeling herd protection and assessments of QoL in children could help more precisely define the conditions under which RV vaccination would be cost-effective in developed countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.